Tag results:

clinical trial

miR-204–Containing Exosomes Ameliorate GVHD-Associated Dry Eye Disease

[Science Advances] Investigators reported that exosomes from MSCs administered as eye drops notably alleviated graft-versus-host disease-associated dry eye disease by suppressing inflammation and improving epithelial recovery in mice and humans.

Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase II Clinical Trial of COVI-MSC in COVID-19 Patients with Persistent Pulmonary Compromise after Recovery (Long-Hauler)

[Sorrento Therapeutics, Inc.] Sorrento Therapeutics, Inc. announced receipt of clearance from ANVISA to proceed with a Phase IIa randomized, placebo-controlled study of intravenous allogeneic adipose-derived MSC to treat post COVID-19 “long haul” pulmonary compromise.

IMV Announces First Patient Dosed in the VITALIZE Phase IIB Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients...

[IMV Inc.] IMV, Inc., a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced a first patient dosed in the VITALIZE Phase IIB clinical trial.

Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-Specified Matched External Control in Part II of Study SRP-9001-102 for the...

[Sarepta Therapeutics] Sarepta Therapeutics, Inc. announced topline results from Part II of Study SRP-9001-102, an ongoing, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and tolerability of a single dose of SRP-9001 in 41 patients with Duchenne muscular dystrophy.

Rubius Therapeutics Announces Dosing of First Patient in Phase I/II Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

[Rubius Therapeutics, Inc.] Rubius Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelia carcinoma and triple-negative breast cancer.

Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase I Clinical Trial of UB-312

[Vaxxinity, Inc.] Vaxxinity, Inc. announced that the first patient with Parkinson’s disease has been dosed with UB-312 in Part B of a double-blinded, placebo-controlled Phase I clinical trial, following completion of Part A of the Phase I trial in healthy volunteers.

Popular